Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

171 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Transcriptional profiling and drug discovery.
Shaw KJ, Morrow BJ. Shaw KJ, et al. Curr Opin Pharmacol. 2003 Oct;3(5):508-12. doi: 10.1016/s1471-4892(03)00110-3. Curr Opin Pharmacol. 2003. PMID: 14559096 Review.
Simultaneous analysis of host and pathogen interactions during an in vivo infection reveals local induction of host acute phase response proteins, a novel bacterial stress response, and evidence of a host-imposed metal ion limited environment.
Motley ST, Morrow BJ, Liu X, Dodge IL, Vitiello A, Ward CK, Shaw KJ. Motley ST, et al. Among authors: shaw kj. Cell Microbiol. 2004 Sep;6(9):849-65. doi: 10.1111/j.1462-5822.2004.00407.x. Cell Microbiol. 2004. PMID: 15272866
Identification of novel inhibitors of bacterial translation elongation factors.
Jayasekera MM, Onheiber K, Keith J, Venkatesan H, Santillan A, Stocking EM, Tang L, Miller J, Gomez L, Rhead B, Delcamp T, Huang S, Wolin R, Bobkova EV, Shaw KJ. Jayasekera MM, et al. Among authors: shaw kj. Antimicrob Agents Chemother. 2005 Jan;49(1):131-6. doi: 10.1128/AAC.49.1.131-136.2005. Antimicrob Agents Chemother. 2005. PMID: 15616286 Free PMC article.
Tetrahydroindazole inhibitors of bacterial type II topoisomerases. Part 2: SAR development and potency against multidrug-resistant strains.
Wiener JJ, Gomez L, Venkatesan H, Santillán A Jr, Allison BD, Schwarz KL, Shinde S, Tang L, Hack MD, Morrow BJ, Motley ST, Goldschmidt RM, Shaw KJ, Jones TK, Grice CA. Wiener JJ, et al. Among authors: shaw kj. Bioorg Med Chem Lett. 2007 May 15;17(10):2718-22. doi: 10.1016/j.bmcl.2007.03.004. Epub 2007 Mar 6. Bioorg Med Chem Lett. 2007. PMID: 17382544
Pyrrolopyrimidine inhibitors of DNA gyrase B (GyrB) and topoisomerase IV (ParE), Part II: development of inhibitors with broad spectrum, Gram-negative antibacterial activity.
Trzoss M, Bensen DC, Li X, Chen Z, Lam T, Zhang J, Creighton CJ, Cunningham ML, Kwan B, Stidham M, Nelson K, Brown-Driver V, Castellano A, Shaw KJ, Lightstone FC, Wong SE, Nguyen TB, Finn J, Tari LW. Trzoss M, et al. Among authors: shaw kj. Bioorg Med Chem Lett. 2013 Mar 1;23(5):1537-43. doi: 10.1016/j.bmcl.2012.11.073. Epub 2012 Dec 8. Bioorg Med Chem Lett. 2013. PMID: 23294697
Pyrrolopyrimidine inhibitors of DNA gyrase B (GyrB) and topoisomerase IV (ParE). Part I: Structure guided discovery and optimization of dual targeting agents with potent, broad-spectrum enzymatic activity.
Tari LW, Trzoss M, Bensen DC, Li X, Chen Z, Lam T, Zhang J, Creighton CJ, Cunningham ML, Kwan B, Stidham M, Shaw KJ, Lightstone FC, Wong SE, Nguyen TB, Nix J, Finn J. Tari LW, et al. Among authors: shaw kj. Bioorg Med Chem Lett. 2013 Mar 1;23(5):1529-36. doi: 10.1016/j.bmcl.2012.11.032. Epub 2012 Dec 5. Bioorg Med Chem Lett. 2013. PMID: 23352267
171 results